Biomarkers in Clinical Trials for Neurodegenerative Diseases

Abstract

Biomarkers play a pivotal role in neurodegenerative disease therapeutics, enabling early diagnosis, disease progression monitoring, and therapeutic efficacy assessment. Advances in biomarker research have led to the integration of biofluid-based, imaging, molecular, and aggregation assays into clinical trials for Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS).

This white paper explores the types of biomarkers used in neurodegenerative disease trials, their role in patient selection and disease monitoring, regulatory considerations, emerging technologies, ethical challenges, and case studies highlighting their impact. 

Please provide your name and your email to download the document.

First & Last name

Business email

Company

Country

I consent to my info being included in Accelsiors’ database.

I have read and agree withAccelsiors’ Privacy Policy & Terms of Use. By submitting this form, I thereby consent to the processing of my personal data in accordance with this Notice.

By submitting your information through this webform, you will be added to our business contact database. We may then reach out to inform you about ACCELSIORS AG’s products, services, and career opportunities that could benefit your organization.

Rest assured, we respect your privacy and will only contact you with relevant, useful information. Your details will never be shared or sold to any third parties without your consent.
You are in full control. If you no longer wish to receive our communications, you can unsubscribe at any time with the click of a button. We make it easy to opt-out.

At ACCELSIORS AG, we strive to be helpful partners to your business, not unwanted solicitors. Our goal is simply to share updates we feel could add value based on your needs and interests. We hope you find our communications worthwhile, but respect your right to choose what is best for you. Please reach out with any questions. We are here to help!

Loading…

We want to ensure you get this document in a timely manner, so don’t hesitate to reach out if you run into any issues accessing it from the email. We are happy to resend it or find an alternative delivery method if needed.

Please feel free to contact us with any questions at

[email protected]